Log in

Relevant bibliographies by topics / 159.9.072: 004.946.5 (043.2)

Contents

Journal articles

Academic literature on the topic '159.9.072: 004.946.5 (043.2)'

Author: Grafiati

Published: 30 May 2022

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic '159.9.072: 004.946.5 (043.2).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "159.9.072: 004.946.5 (043.2)"

1

Sierra-Díaz, Diana Carolina, Adrien Morel, Dora Janeth Fonseca, et al. "Abstract P3-07-05: Genetic profile of germline mutations in unselected women with breast cancer in a Colombian population." Cancer Research 82, no. 4_Supplement (2022): P3–07–05—P3–07–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-07-05.

Full text

Abstract:

Abstract Introduction In Colombia Breast cancer (BC), is the most frequent and has the highest mortality rate among all types of cancer. There are few studies of the genomic profile in unselected affected population by BC in Colombia. Some of these studies have only tested the presence of variants reported as founders named “Colombian Profile”.We conducted a large-scale genomic analysis using Whole Exome Sequencing (WES) to evaluate germline mutations in unselected BC patients. Methods This trial included 299 unselected BC female patients aged over 18 years old, without personal and family his

APA, Harvard, Vancouver, ISO, and other styles

2

Joh, Jae Won, Angel Callejas, Wendy Wong, Harvey Joel Cohen, Kari Nadeau, and Michael Jeng. "Role of Fas/FasL Pathway in Pediatric Idiopathic Neutropenia." Blood 110, no. 11 (2007): 3291. http://dx.doi.org/10.1182/blood.v110.11.3291.3291.

Full text

Abstract:

Abstract Idiopathic neutropenia in children is marked by low neutrophil counts (<1500/ul) circulating in the peripheral blood in patients whose disease spontaneously develops unrelated to drugs, cancers, specific antibodies, or known genetic deficiencies. Neutrophils, PBMCs and plasma were purified/obtained from 24 subjects (n=17 acute and n=7 chronic) with idiopathic neutropenia, aged 3 months to 11 yrs. After screening a number of cytokines (IL-2, IL-4 IL-6, IL-8, IL-10, IFN-γ, TNF-α), growth factors (GCSF), cell death factors (Fas, FasL, Granzymes/Perforin), and chemokines (CCL5, XCL1, X

APA, Harvard, Vancouver, ISO, and other styles

3

Lozano, Miguel, Ana Galan, Roberto Mazzara, Laurence Corash, and Gines Escolar. "Leucocyte-Reduced Buffy Coat Platelet Concentrates (BCPC) Treated with INTERCEPT™ Stored up to 7 Days: Hemostatic Function in a Whole Blood Flow System." Blood 106, no. 11 (2005): 956. http://dx.doi.org/10.1182/blood.v106.11.956.956.

Full text

Abstract:

Abstract Background: The risk of bacterial growth has limited the shelf life of platelet concentrates (PC) to 5 days. Modern platelet storage containers facilitate storage for up to 7 days, if bacterial contamination is prevented. INTERCEPT (Baxter, La Chatre, France; Cerus, Concord, CA) photochemical treatment (PCT) for pathogen reduction based on amotosalen (150μM) and UVA illumination (3 J/cm2) inactivates high titers of bacteria in PC (Transfusion2004; 44: 1496–1504). Adhesion and aggregation of platelets to injured vascular surfaces are critical aspects of platelet hemostatic function. In

APA, Harvard, Vancouver, ISO, and other styles

4

Castrejon, I., J. Molina Collada, C. Perez-Garcia, et al. "POS1439 CANCER IN PATIENTS WITH RHEUMATIC DISEASES EXPOSED TO DIFFERENT BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN REAL-WORLD CLINICAL PRACTICE: DATA FROM A MULTICENTER REGISTER." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1063. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3834.

Full text

Abstract:

BackgroundExtensive evidence has confirmed no increased risk of cancer associated to either conventional synthetic DMARDs or anti-TNF in patients with rheumatic diseases. The risk of cancer in biologic (bDMARDs) different to anti-TNF and targeted synthetic (tsDMARDs) is considerably less investigated. As new therapies are emerging, more data in real-world registries are needed to confirm safety in other treatment groups.ObjectivesTo compare the risk of cancer of tsDMARDs and other bDMARDs versus anti-TNF in patients with rheumatic diseases.MethodsData of patients enrolled in BIOBADASER 3.0 up

APA, Harvard, Vancouver, ISO, and other styles

5

Sesin, C., G. Gallo, A. Gellett, et al. "POS1033 SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS OF 4 CLINICAL TRIALS." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 789.1–789. http://dx.doi.org/10.1136/annrheumdis-2021-eular.567.

Full text

Abstract:

Background:Patients with psoriatic arthritis (PsA) require long-term treatment, which may lead to adverse events (AEs). Ixekizumab, an interleukin-17A antagonist, is approved for the treatment of adults with active PsA.Objectives:We report a summary of safety outcomes for patients enrolled in 4 PsA studies with up to 3 years of exposure to ixekizumab.Methods:This integrated safety analysis included all patients with PsA who received at least 1 dose of ixekizumab (80 mg every 2 or 4 weeks) in 4 clinical trials (NCT01695239, NCT02349295, NCT02584855, NCT03151551). Safety outcomes included treatm

APA, Harvard, Vancouver, ISO, and other styles

6

Itzykson, Raphael, Alex Smith, Theo M. de Witte, et al. "Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry." Blood 120, no. 21 (2012): 700. http://dx.doi.org/10.1182/blood.v120.21.700.700.

Full text

Abstract:

Abstract Abstract 700 Purpose: Prognosis of lower (IPSS low/int-1) risk MDS is heterogeneous. Current prognostic systems rely on single time point cytopenia values (Hb level, ANC, PLT counts) at diagnosis (classical or revised IPSS [IPSS-R] Greenberg, Blood 2012) or during evolution (time-dependent IPSS/WPSS). Capturing the dynamics of continuous parameters can yield independent prognostic information as exemplified by lymphocyte time doubling in CLL. We analyzed the prognostic relevance of the kinetics of Hb, ANC and PLT in lower-risk MDS patients (pts) included in the prospective EUMDS regis

APA, Harvard, Vancouver, ISO, and other styles

7

Kim, Kyu-Pyo, Mariano Ponz Sarvise, Teresa Macarulla, et al. "Abstract CT212: Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC." Cancer Research 84, no. 7_Supplement (2024): CT212. http://dx.doi.org/10.1158/1538-7445.am2024-ct212.

Full text

Abstract:

Abstract Background: Adenosine signaling can suppress the immune microenvironment and promote tumor immunity in many cancers, including pancreatic ductal adenocarcinoma (PDAC). Etruma, a dual adenosine A2a/A2b receptor antagonist, was evaluated in combination with atezo (anti-programmed death-ligand 1 [PD-L1] antibody) and chemo vs chemo alone (control) in patients (pts) with first-line PDAC in the MORPHEUS-PDAC study (NCT03193190). Methods: Pts were randomized to receive atezo (840 mg IV; Days 1 and 15 of 28-day cycles) + etruma (150 mg orally once daily) + chemo (nab-paclitaxel 125 mg/m2 IV

APA, Harvard, Vancouver, ISO, and other styles

8

Mohamed, Fawzy, El Naggar Ayman, Kazamel Gada, and Fawzy Mohamed. "Comparative study between thrombolytic therapy and surgery in 30 cases of acute left sided prosthetic valve thrombosis." Biolife 5, no. 3 (2022): 361–69. https://doi.org/10.5281/zenodo.7371013.

Full text

Abstract:

<strong>ABSTRACT</strong> <strong>Introduction:</strong> Prosthetic valve thrombosis is a potentially life-threatening complication associated with high morbidity and mortality. Transthorasic and transoesophageal echocardiography play an important role to the diagnosis and provides incremental information about the optimal treatment strategy. Guidelines differ on whether surgical treatment or fibrinolysis should be the treatment of choice for the management of left-sided prosthetic valve thrombosis. The aim of the study is to compare between thrombolytic therapy and surgery regarding success,

APA, Harvard, Vancouver, ISO, and other styles

9

Fattizzo, Bruno, Raffaella Pasquale, Monica Carpenedo, et al. "Clinical and Morphologic Predictors of Outcome in a Multicenter Cohort of ITP Patients Treated with Trombopoietin Analogues." Blood 132, Supplement 1 (2018): 3764. http://dx.doi.org/10.1182/blood-2018-99-116627.

Full text

Abstract:

Abstract Background: The role of bone marrow response in patients with immune thrombocytopenia (ITP) has gained paramount importance since the last 10 years, with the demonstrations that marrow megakaryocytes (MGK) are unable to properly compensate platelets peripheral destruction. TPO receptor agonists (TPOa), namely romiplostim (ROMI) and eltrombopag (EPAG), by stimulating megakaryopoiesis are able to induce a response in 74% to 94% of cases in clinical trials. However, real world use of these drugs has shown frequent changes in individual dose requirement, the possibility of treatment disco

APA, Harvard, Vancouver, ISO, and other styles

10

Du, Mengxi, and Fang Fang Zhang. "Dietary Supplement Use Among Adult Cancer Survivors in the United States." FASEB Journal 31, S1 (2017). http://dx.doi.org/10.1096/fasebj.31.1_supplement.168.6.

Full text

Abstract:

BackgroundMany cancer patients initiated supplement use after cancer diagnosis and yet the effect of supplement use on survival has not been established. The trend of and factors associated with dietary supplement use in cancer survivors warrant further investigation.MethodsWe examined the trend of dietary supplemental use in 1,902 adult cancer survivors who participated in the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2012, and compared the frequency of supplement use in cancer survivors to that of 3,804 individuals with no history of cancer who were matched to th

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!